Alymsys (bevacizumab-maly) vs IBI305

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline

Alymsys (bevacizumab-maly)

Marketed by Amneal Pharmaceuticals

Approved in Non-Small Cell Lung Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

IBI305

Marketed by Innovent Biologics

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT02954172 · Phase 3 · completed

This was a randomized, double-blind, active-controlled trial with 450 enrolled participants (220 and 221 in the reported primary analysis groups). Its primary clinical endpoint, objective response rate at 18 weeks, met the prespecified equivalence criterion: 44.3% with IBI305 versus 46.4% with bevacizumab, with the 90% confidence interval for the odds ratio entirely within the 0.75–1.33 equivalence margin.

Reported efficacy

Objective Response Rate (18 weeks): Objective response rate at 18 weeks: 44.3% IBI305 (n=221) vs 46.4% bevacizumab (n=220); odds ratio 0.90 (90% CI 0.756–1.077), prespecified equivalence margin 0.75–1.33. (met)

Result source: NCT02954172

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlymsys (bevacizumab-maly)IBI305
PFS, median8.3 vs 8.6vs Avastinwk 52 · n 315NCT032961638.4 vs 8.3vs Bevacizumabn 221NCT02954172
OS, median—Not reported18.0n 221NCT02954172
ORR40.3% vs 44.6%vs Avastinwk 18 · n 315NCT0329616344.3% vs 46.4%vs Bevacizumabwk 18 · n 221NCT02954172
Duration of response, median—Not reported—Not reported

PFS, median

Alymsys (bevacizumab-maly)
8.3 vs 8.6vs Avastinwk 52 · n 315NCT03296163
IBI305
8.4 vs 8.3vs Bevacizumabn 221NCT02954172

OS, median

Alymsys (bevacizumab-maly)
—Not reported
IBI305
18.0n 221NCT02954172

ORR

Alymsys (bevacizumab-maly)
40.3% vs 44.6%vs Avastinwk 18 · n 315NCT03296163
IBI305
44.3% vs 46.4%vs Bevacizumabwk 18 · n 221NCT02954172

Duration of response, median

Alymsys (bevacizumab-maly)
—Not reported
IBI305
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Alymsys (bevacizumab-maly): 3 of 4 rows · IBI305: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlymsys (bevacizumab-maly)IBI305
Dropout rate
34.3%a
NCT03296163 · Phase 3
1.3%a
NCT02954172 · Phase 3 · combination
Discontinued due to AEs
—a
NCT03296163 · Phase 3
—a
NCT02954172 · Phase 3 · combination
Serious AEs
18.6%a
NCT03296163 · Phase 3
33.5%a
NCT02954172 · Phase 3 · combination
Most frequent reported AEs
a
alopecia 49.8%
anemia 32.5%
nausea 15.1%
NCT03296163 · Phase 3
a
white blood cell count decreased 71.9%
neutrophil count decreased 70.5%
platelet count decreased 50.4%
NCT02954172 · Phase 3 · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alymsys (bevacizumab-maly)'s landscape · IBI305's landscape